TrialAIDS (London, England)2015

Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.

Pablo Tebas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.